What Is Tigecycline and Why Use PK Software for It?
Tigecycline, a glycylcycline antibiotic, treats complicated infections like skin and intra-abdominal cases. Its pharmacokinetics (PK) stand out due to low steady-state volume of distribution (7-10 L/kg), biliary elimination (over 50%), and minimal renal clearance (<20%). PK software handles it by modeling these traits—high tissue penetration, nonlinear clearance at high doses, and enterohepatic recirculation—to simulate dosing, predict exposure, and optimize therapy in simulations or therapeutic drug monitoring (TDM).[1][2]
Key PK Parameters Software Incorporates
Software like NONMEM, Phoenix NLME, or GastroPlus inputs tigecycline's parameters:
- Clearance: Primarily hepatic (59 mL/h/kg), reduced in liver impairment; models use population PK data adjusting for covariates like age, weight, and creatinine clearance.
- Half-life: 27-42 hours post-loading dose, extending to 57 hours at steady state due to recirculation.
- Bioavailability: Near 100% IV; oral models are rare but simulate analogs.
Programs apply one- or two-compartment models with Michaelis-Menten kinetics for saturation at doses >100 mg, fitting clinical data from Phase 3 trials.[3][4]
| Parameter | Typical Value | Software Handling |
|-----------|---------------|-------------------|
| Vss | 7-10 L/kg | Scales by body weight; tissue compartment for lung/IA penetration |
| CL | 0.5-1 L/h | Covariate-adjusted (e.g., Child-Pugh score) |
| t1/2 | 30-60 h | Time-dependent due to autoinduction |
| Protein Binding | 71-89% | Influences free fraction in Monte Carlo simulations |
Common Software Tools and Their Tigecycline Models
- NONMEM/Monolix: Population PK analysis from studies like OPTIMIZE trial; handles variability (30-50% inter-patient) via Bayesian methods for TDM in ICU patients.
- Simcyp or GastroPlus: PBPK for drug-drug interactions (e.g., with warfarin via CYP3A4 induction); predicts biliary excretion and fecal recovery (33-59%).
- InsightRX or DoseMeRx: Clinical TDM platforms; integrate tigecycline assays for Bayesian forecasting, adjusting for obesity (Vss increases 20-30%).[5]
Open-source like Mrgsolve scripts tigecycline for R users, pulling parameters from FDA labels.
Challenges Software Faces with Tigecycline
Nonlinearity above 100 mg complicates linear models—software switches to nonlinear mixed-effects. Critically ill patients show 40% higher clearance; tools use covariates like SOFA score. Limited pediatric data requires extrapolation. Drug interactions (e.g., rifampin boosts clearance 50%) demand interaction modules.[6]
How Clinicians Use It for Dosing
Software simulates AUC/MIC targets (>17-25 mg*h/L for Enterobacterales) post-100 mg load + 50 mg q12h. In obesity or renal failure, it recommends weight-based dosing (2-3 mg/kg load). Real-world: Reduces underexposure in 25% of patients per PK/PD studies.[7]
Alternatives if Software Lacks Tigecycline Data
Build custom models from literature (e.g., PubMed PK sets) or use generic antibiotic modules tuned to glycylcyclines. Competitors like meropenem have pre-built libraries; migrate data via XML imports.
[1]: FDA Tigecycline Label
[2]: DrugPatentWatch - Tigecycline Patents
[3]: Abdul-Aziz et al., Clin Pharmacokinet (2020) - Population PK review
[4]: pharmacokinetic-parameters.com/tigecycline
[5]: InsightRX platform documentation
[6]: Roberts et al., Crit Care Med (2014) - Tigecycline PK in sepsis
[7]: EUCAST PK/PD targets for tigecycline